GA
BMRN icon

Geneva Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Geneva Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.95M Buy
21,507
+35
+0.2% +$3.18K 0.03% 222
2017
Q1 		$1.89M Sell
21,472
-2,514
-10% -$224K 0.03% 221
2016
Q4 		$1.99M Buy
23,986
+419
+2% +$36K 0.04% 209
2016
Q3 		$2.18M Hold
23,567
– – 0.04% 186
2016
Q2 		$1.83M Sell
23,567
-7,745
-25% -$658K 0.04% 209
2016
Q1 		$2.58M Buy
31,312
+8,560
+38% +$696K 0.05% 157
2015
Q4 		$2.38M Sell
22,752
-105
-0.5% -$11K 0.05% 178
2015
Q3 		$2.41M Sell
22,857
-7,080
-24% -$946K 0.05% 168
2015
Q2 		$4.09M Sell
29,937
-595
-2% -$73.7K 0.07% 145
2015
Q1 		$3.81M Buy
30,532
+7,310
+31% +$775K 0.07% 149
2014
Q4 		$2.1M Buy
23,222
+1,935
+9% +$161K 0.04% 192
2014
Q3 		$1.54M Buy
21,287
+1,255
+6% +$82.5K 0.03% 233
2014
Q2 		$1.25M Buy
20,032
+1,900
+10% +$115K 0.02% 280
2014
Q1 		$1.24M Buy
18,132
+742
+4% +$54.7K 0.02% 273
2013
Q4 		$1.22M Sell
17,390
-194,736
-92% -$13.2M 0.02% 232
2013
Q3 		$15.3M Buy
212,126
+195,946
+1,211% +$13M 0.32% 85
2013
Q2 		$902K Buy
+16,180
New +$1.01M 0.02% 227

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geneva Advisors's BMRN Position: Q2 2017 in Review

Geneva Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 0.16% in Q2 2017, buying an estimated $3.18K and bringing the position to 21,507 shares worth $1.95M. The position accounts for 0.03% of the portfolio, ranked #222.

Geneva Advisors first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $15.3M in Q3 2013. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Geneva Advisors held 21,507 shares of BioMarin Pharmaceuticals worth $1.95M as of Q2 2017.
  • Geneva Advisors bought 35 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $3.18K.
  • BioMarin Pharmaceuticals made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #222 holding.
  • Geneva Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's BioMarin Pharmaceuticals position peaked at $15.3M in Q3 2013.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.